17,137 Shares in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Purchased by Virtu Financial LLC

Virtu Financial LLC acquired a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 17,137 shares of the company’s stock, valued at approximately $58,000.

A number of other institutional investors also recently modified their holdings of the stock. Geode Capital Management LLC grew its stake in shares of Xeris Biopharma by 2.9% during the third quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock valued at $9,502,000 after purchasing an additional 93,091 shares during the last quarter. Walleye Capital LLC bought a new position in Xeris Biopharma in the 3rd quarter valued at $3,197,000. Essex Investment Management Co. LLC acquired a new stake in shares of Xeris Biopharma in the 4th quarter valued at $1,610,000. Wellington Management Group LLP increased its stake in shares of Xeris Biopharma by 11.7% in the 3rd quarter. Wellington Management Group LLP now owns 471,644 shares of the company’s stock valued at $1,344,000 after buying an additional 49,535 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of Xeris Biopharma by 20.8% during the third quarter. JPMorgan Chase & Co. now owns 391,960 shares of the company’s stock worth $1,117,000 after acquiring an additional 67,557 shares during the last quarter. 42.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on XERS shares. HC Wainwright reiterated a “buy” rating and set a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Piper Sandler reissued a “neutral” rating and issued a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Leerink Partners lifted their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, March 7th. Finally, Craig Hallum increased their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $6.10.

Insider Transactions at Xeris Biopharma

In related news, insider Beth Hecht sold 40,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the sale, the insider now directly owns 1,353,510 shares of the company’s stock, valued at approximately $7,349,559.30. This represents a 2.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.56% of the stock is currently owned by insiders.

Xeris Biopharma Trading Down 1.6 %

Shares of Xeris Biopharma stock opened at $5.49 on Tuesday. The stock’s fifty day simple moving average is $4.18 and its 200 day simple moving average is $3.54. The company has a market capitalization of $845.13 million, a PE ratio of -12.20 and a beta of 2.32. Xeris Biopharma Holdings, Inc. has a 12 month low of $1.69 and a 12 month high of $6.07.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.